reason report
highlight massiv meet mani
bottom line follow busi american societi hematolog
meet publish recap note summar
import takeaway confer leerink therapeut research
analyst publish research note prior meet
separ note meet two meet
research cover gamut hematolog hematology-oncolog
hemophilia rare anemia leukemia lymphoma
myeloma year describ attende
bigger mani way investor meet
showcas progress academia industri make
breakthrough technolog gene therapi cellular therapi
rnai well new advanc tradit biopharmaceut
small molecul drug even leerink research staff
attend meet could cover entireti
therapeut advanc present confer summari note
provid investor synopsi highlight
major advanc meet well link relev research
note associ stock therapeut indic discuss
key takeaway start page
list note alphabet ticker appear page
sortabl version may access
full content confer note start page
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
takeaway
myeloma highlight new frontlin standard care emerg multipl
later line b-cell matur antigen bcma target therapi one highlight
year jnj maia trial show impress reduct risk
progress overal respons rate compar rd control arm
result like follow approv darzalex-revlimid-dexamethason drd
us earli rapid adopt among non-transpl elig newli diagnos myeloma
patient disrupt current gold standard posit velcade-revlimid-dexamethason
vrd rd patient popul one secondari effect develop
make difficult product even advanc front line patient popul
given like month median treatment durat progress free surviv
second line set result trial venetoclax kyproli dexamethason vcd
vkd velcade-cyclophosphamide-dexamethason venetoclax-kyprolis-dexamethason
relaps refractori myeloma produc overal respons rate cr
better respons occur even patient highli refractori prior treatment
suggest venetoclax signific synergi proteasom inhibitor perhap
drug class diseas studi on-going mani patient remain
treatment like lead addit trial venetoclax set indic
final bcma becom one hottest keenli studi target
hematolog malign less dozen car-t program highlight
well sever bcma target antibodi construct bcma excel target myeloma
approach show consist high respons rate gener
high proport deep respons complet respons cr stringent cr scr
studi investig report minim residu diseas neg mrd-ve rate
typic align rate cr scr outstand question
program durabl respons far littl data beyond month
even program bluebird/celgen report month median
suggest least refractori patient durat respons
bcma treatment might still rel short like car-t approach bcma come
liabil typic consist cytokin releas syndrom neurotox
advers event appear milder target treatment non-hodgkin
lymphoma nhl acut lymphoblast leukemia still like limit use
treatment major center treatment resist refractori higher risk patient
amgen bcma target bite antibodi repres altern approach diseas
target report impress respons rate dose find studi
optim dose howev respons came price signific safeti toler
liabil seriou fatal infect dose limit continu iv infus month
time like limit rel short durat treatment rel
late line patient second gener version product could much
commerci viabl version product enter clinic develop
celg op maia celgen biggest success luspatercept
phase trial medalist result md trial first present plenari session
meet confirm favor efficaci safeti alreadi disclos celgen
suggest beta thalassemia data also present meet main caus
delay file timelin like certainli expect approv
myelodysplast syndrom md earli celgen reiter peak revenu
guidanc product confirm guidanc includ current on-going
naiv ring sideroblast neg rs-ve well myelofibrosi celgen also benefit
short term success maia trial although compani explain market
penetr high front line myeloma us littl increment
share avail even maia result longer term continu boost durat
compani face loss exclus time today patient start maia regimen
reach end expect treatment durat nhl result augment trial
provid opportun compani file approv regimen follicular
lymphoma gener increment revenu remaind product
patent life celgen also benefit small amount increment data present
car-t program myeloma program show
efficaci compar better shown show hint
greater persist cell durabl effect far convinc celgen
assert juno program offer path routin outpati administr car-
treatment nhl program continu show signific number
case cytokine-releas syndrom neurotox believ common
enough sever enough patient go treat forese
futur guidanc tertiari referr hospit signific transplant volum
chronic lymphocyt leukemia cll cll focu imbruvica multipl phase
studi compar imbruvica standard-of-car chemoimmunotherapi guarante
abbvi drug use major treatment nave cll patient link strength
imbruvica data higher respons rate extend howev need
continu treatment erad minim residu diseas leav room improv
among medicin like benefit imbruvica shortcom venclexta
appear promis combin imbruvica becom appar futur
cll treatment potent combin regiment year fix durat follow
watch wait mainten treatment other
mp strength imbruvica data make near/mid-term consensu
revenu forecast appear conserv estim imbruvica penetr cll
could increas current new treatment start next year
drive higher sale profit abbvi largest product longer term imbruvica like
retain substanti share set even new competitor enter market although
revenu could come pressur fix durat treatment ever wide accept still
well posit scenario would like benefit imbruvica
venclexta use combin although larger random studi need confirm
op becam ravulizumab thu ultomiri investig present
final result second two pivot trial alexion ravulizumab rav previous
known soon known ultomiri compani previous present
first efficaci result european hematolog meet june pivot switch
trial also use current label dose soliri control arm weekli even
though patient reportedli stabl well control dose soliri mani
patient requir higher dose stabil condit comparison investig
dose ravulizumab load week achiev much
complet consist target inhibit higher plasma exposur roch much
anticip present confirm mani best featur
ravulizumab albeit half-lif long ravulizumab mean
best day could administ monthli two weekli schedul vs
weekli dose rav hand clear formul suitabl
iv sc administr expect studi pivot trial
like avail launch isnt suggest take market
antibodi better ravulizumab like drug least part
market product within year approv
mp investor weigh threat frontlin acut myeloid leukemia aml
exit share pressur follow superl frontlin aml data
venclexta hma exceed cooper studi idhifa given venclexta
favor toler broad popul resurg safeti concern differenti
syndrom isocitr dehydrogenas idh inhibitor mani investor unsur role
idh class frontlin aml although see venclexta like becom signific
factor aml market continu see number frontlin opportun idh
agent includ combin intens induct chemo pathway forward
venclexta less clear updat data idh inhibitor plu chemotherapi
robust decreas rate differenti syndrom see go forward phase
hovon trial test either tibsovo idhifa expect start immin
snda tibsovo monotherapi patient elig treatment expect file
data also meet phase agil trial tibsovo vidaza on-going
enrol complet believ increment updat tibsovo combin
hma monotherapi treatment inelig patient could restor investor
op symptomat relief broad therapeut window suggest domin
market posit avapritinib sm updat avapritinib data advanc system
mastocytosi asm show respons continu broad deep highli
durabl result new patient report outcom questionnair demonstr
treatment associ signific reduct symptom asm well
improv qualiti life patient indol sm enrol current trial
experienc signific reduct mast cell burden key demonstr activ
less sever patient expect translat symptomat relief on-going phase
pathfind trial single-arm pivot trial avapritinib asm intend begin
pioneer trial phase single-arm pivot indol smolder sm patient
anticip next updat program like european hematolog
associ eha meet
op announc top-lin result phase sadal studi evalu
selinexor monotherapi relapsed/refractori r/r diffus larg b-cell lymphoma dlbcl patient
later line set overal view data favor vs low bar set
medacorp key opinion leader kol spoken highlight studi
salvag therapi benchmark although sadal patient popul would sicker
elig high-dos chemotherapi autolog stem cell transplant rescu believ
result bode well selinexor futur r/r dlbcl place dlbcl treatment
landscap plan submit nda acceler approv
arql op updat data arql phase dose-escal studi arq revers
inhibitor wild type mutant btk relapsed/refractori hematolog
malign present notabl present highlight initi clinic data
therapeut dose arq overal view data still earli posit takeaway
includ increas anti-tumor activ observ increas dose good safeti profil
support continu dose escal partial respons pr achiev patient
follicular lymphoma fl investor may disappoint lack respons
achiev patient chronic lymphocyt leukemia cll preliminari data would
emphas cll patient treat highest dose cohort present
scan time addit cll patient heavili pretreat
median prior therapi repres sicker patient popul arql intend patient
popul ultim cll landscap remain dynam competit medacorp
kol check highlight potenti arq continu see potenti long-term
appreci arq becom de-risk addit clinic updat
op present encourag biomarker-enrich data updat on-going
phase tipifarnib studi peripher cell lymphoma overal view updat
encourag like exceed street expect data still earli compel
stori emerg tipifarnib inhibitor may open addit opportun
beyond recal look identifi valid biomark prospect basi
tipifarnib hematolog malign view opportun tipifarnib outsid solid tumor
overlook import driver upsid vs street expect
op investor debat focus precondit safeti bcma
competit disclos one sickl cell diseas scd patient
studi develop myelodysplast syndrom md discuss investor
potenti implic safeti profil lentiglobin lentivir vector-bas
gene therapi hotli debat secondari malign known clinic risk
precondit alkyl agent mark case tragedi patient involv
famili surpris scientif standpoint view see classif
md event unrel treatment someth technic busulfan pre-
condit part treatment protocol lentiglobin patient
sever scd patient gene therapi would use precondit compon
compet treatment regimen well busulfan wide use purpos result
commerci regulatori relev event debat
increas competit bcma seen see stay ahead pack
rest pipelin continu deliv believ retain sizabl lead
anti-bcma car-t therapi could rais bar even time competitor
readi pivot data first-gener product view orr
complet respons cr rate median progress free surviv jnj
program promis note respons rate like inflat patient
less advanc diseas baselin earli data encourag view product
better fit advanc patient inelig car-t would benefit
earli off-the-shelf intervent elsewher pipelin present encourag data
transfusion-depend -thalassemia tdt patient studi
readout impress data group -- patient treat cell prepar
compani improv collect manufactur process -- sickl cell diseas scd
leerink equiti research report american societi hematolog confer
 what new cll imbruvica like becom ubiquit market perform
-- flash competit idh safeti concern could pressur updat market perform
-- flash updat suggest tibsovo signific role aml despit skeptic market perform
 tibsovo launch encourag posit develop regulatori updat market perform
asln -- flash data earli multipl readout market perform
bgne -- flash zanubrutinib updat mcl re-affirm differenti outperform
bgne updat execut continu zanubrutinib time slip trim pt outperform
 md like pressur rel posit
 crowd could bcma get celgen look like winner
 luspatercept outlook depend celgen execut
 preview planner
biopharma/ash late breaker signal chang soc cll myeloma chemo disappear
-- flash luspatercept abstract confirm robust md effect less impress beta-th
-- flash ahead pack competit still chase bcma outperform
celg event cover revlimid ip luspatercept result cellular therapi outperform
celg could drd treatment what month myeloma outperform
-- flash tazemetostat r-chop toler activ dlbcl market perform
-- flash updat highlight earli aml data investor focu remain forward-i outperform
-- flash posit updat jakafi pemigatinib program market perform
 posit sadal result nda submiss pt outperform
-- flash flotetuzumab updat in-lin sophia readout outperform
-- flash final progress long herald bispecif nhl outperform
-- flash ab show given weekli clear threat ultomiri outperform
-- flash earli label expans suggest upsid rev guidanc less risk outperform
-- flash impress adcetri data opdivo combo r/r chl outperform
-- flash data show earli efficaci multipl bispecif readout outperform
-- flash abstract highlight earli efficaci present outperform
reason report
what new cll imbruvica like becom
bottom line american societi hematolog meet
week sever highli impact phase result
mp /jnj op imbruvica ibrutinib highlight practic
chang context treat individu treatment-nav
chronic lymphocyt leukemia cll result phase
allianc studi subject late
break plenari oral present drew plenti interest
treat hematologist result critic term
achiev long-term guidanc risk-adjust revenu
imbruvica non-risk adjust us sale
expect come cll sale maintain market
perform rate price target share
signific increment result imbruvica came
allianc trial trial compar imbruvica alon
combin rituxan standard care chemoimmunotherapi
regimen fcr br strongli posit result trial mean
futur use imbruvica go increas significantli
sever segment drug still rare use new segment
includ non-elderli popul patient previous consid
candid aggress chemoimmunotherapi
analysi suggest imbruvica frontlin share cll could
increas current base strength
recent data current estim least imbruvica
sale cll use cll set base
medacorp feedback use current us revenu run-rat analysi
suggest increment penetr cll us could contribut
top-lin revenu next two year recent
consensu estim forecast total us imbruvica growth
suggest may near-term upsid
street forecast howev penetr addit
indic necessari achiev aggress long-
term financi guidanc import medicin forecast
abbvi share global imbruvica sale grow
imbruvica estim consensu
increment inform present reinforc convict
outlook product remain one brightest part
abbvi portfolio key driver jnj pharma busi well
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
provid exclus use mari ellen eagan leerink pm
price target per share stock rate market perform
transit corpor ownership success larg independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil matur biotechnolog compani remain highli depend
singl franchis humira sale total sale suggest
us valuat still discount compar diversifi peer
multipl settlement us biosimilar entrant postpon eros brand domest
eros europ underway appear sharper faster prior
product abbvi abil control destini may fade depend action
new entrant even us would surpris see pressur humira
growth new entrant chang regul legal oversight manag care
pbm contract still expect oncolog product imbruvica venclexta becom
signific product gener revenu
compani hcv product maintain roughli pariti share competitor gilead
scienc look compani array promis late-stag clinic
medicin inflamm metabol diseas struggl expand oncolog
franchis beyond imbruvica venclexta current pipelin establish product
contribut singl digit revenu growth unlik off-set massiv
headwind face biosimilar enter market compet humira
ibrutinib disrupt treatment algorithm cll
three oral present highlight immedi practic chang cll
allianc younger/fit cll patient would almost alway
receiv chemoimmunotherapi regimen fludarabine/cyclophosphamide/rituxan fcr older
patient comorbid would like treat ibrutinib monotherapi individu
fall two categori tend receiv
therapi exhibit highlight colleagu andrew beren recent
cll medacorp survey link estim share ibrutinib cll predominantli
elderly/unfit popul new transform data present suggest share
ibrutinib could increas substanti toward rang base result ibrutinib
regimen versu br fcr chlorambucil highlight
provid exclus use mari ellen eagan leerink pm
late break abstract present tuesday highlight data phase studi
ibrutinib rituxan i-r compar gold standard chemoimmunotherapi regimen fcr
young/fit treatment nave cll patient note fcr wide consid
activ treatment cll prefer regimen subject abl toler potent cytotox
agent ibrutinib use frontlin set limit individu
gener thought frail toler fcr presum advantag fcr
ibrutinib although head head studi conduct
elig popul studi treatment nave patient year age subject
delet allow studi ibrutinib alreadi known
efficaci popul subject randomli assign either ibrutinib
progress rituxan cycl standard dose fcr cycl total subject
dose median follow-up time month interim analysi perform
show clear progression-fre surviv benefit i-r fcr cross pre-
specifi boundari superior
median age year studi hazard ratio progress free surviv i-r
intention-to-treat popul exhibit importantli perform fcr
par actual slightli better outcom prior studi regimen benefit i-
 fcr also reflect analys mutat statu age perform statu
provid exclus use mari ellen eagan leerink pm
addit benefit magnifi ighv unmut higher risk subpopul
patient overal surviv also improv i-r i-r
cohort total death three unrel cll
term safeti fcr associ greater myelosuppress infecti
complic expect differ statist signific exhibit
total fcr treat subject compar i-r treat grade higher
advers event atrial fibril bleed hypertens
diarrhea occur higher frequenc i-r arm investig note
frequenc high grade advers event i-r studi young/fit patient much
less i-r arm allianc studi elderli patient
provid exclus use mari ellen eagan leerink pm
exhibit statist advantag ibrutinib-rituxan advers event rate
overal investig conclud combin ibrutinib-rituxan confer
efficaci toler advantag fcr immedi practic chang implic
establish ibrutinib-bas therapi efficaci first-lin therapi patient
cll remain question relat studi whether rituxan confer addit
benefit ibrutinib monotherapi popul base result allianc
studi also despit overal surviv advantag i-r well establish fcr
provid function cure approxim treatment nave cll patient flatten
surviv curv year addit follow-up may necessari convinc specialist
long-term outcom i-r exceed fcr particularli context
need indefinit treatment ibrutinib
allianc studi phase trial investig ibrutinib /- rituxan versu bendamustine-
rituxan treatment-nav elderli cll patient studi select present
plenari scientif session simultan publish new england journal
medicin day link total subject random either standard
schedul b-r ibrutinib monotherapi ibrutinib-rituxan median age year
provid exclus use mari ellen eagan leerink pm
major ecog perform statu popul could defin elderli fit
fall precis young/fit popul gener treat fcr
elderly/unfit popul like receiv ibrutinib alon per fda label given
median age diagnosi cll popul repres sizeabl proport
incid cll popul real world ibrutinib previous studi
random head head fashion b-r set bendamustine-rituxan gener
consid efficaci drug regimen group patient
intention-to-treat analysi show overal respons rate b-r ibrutinib
monotherapi i-r exhibit chemoimmunotherapi regimen deepest
respons show complet respons cr rate compar ibrutinib alon
i-r minim residu diseas neg statu also highest chemoimmunotherapi
exhibit respons higher ibrutinib deeper bendamustin
median follow-up month two ibrutinib regimen statist better
b-r primari endpoint progress free surviv median month b-r
reach either ibrutinib mono i-r exhibit hazard ratio diseas progress
ibrutinib alon vs b-r i-r vs b-r signific effect maintain
across subgroup analys gener favor ibrutinib monotherapi regimen b-r
surprisingli ibrutinib monotherapi i-r cohort essenti ident
suggest increment benefit regimen
surpris find indic strong effect confer ibrutinib cll cell howev
lower cr mrd rate ibrutinib arm suggest diseas activ fulli
provid exclus use mari ellen eagan leerink pm
suppress long-term continu ibrutinib need least monotherapi
exhibit advantag ibrutinib b-r
woyach et al new england journal medicin
interestingli analysi overal surviv month signific differ
three group overal surviv os favor b-r compar
i-r exhibit investig hypothes lack differ os benefit
result short follow-up subject progress b-r may subsequ
treat ibrutinib extend surviv compar altern treatment
ibrutinib-experienc patient obviou limit data treatment ibrutinib
monotherapi must continu indefinit order realiz benefit remiss
b-r deeper treatment cours fix fail b-r mean ibrutinib alway
avail line option earli progress nevertheless reaction
hematologist posit physician also encourag
advantag ibrutinib arm b-r even pronounc higher risk complex
karyotyp subpopul data suggest substanti proport treatment-nav cll
patient meet enrol criteria studi treat ibrutinib monotherapi
b-r chlorambucil contain regimen
provid exclus use mari ellen eagan leerink pm
exhibit overal surviv differ three arm
third phase result note immedi practic chang implic cll
studi ibrutinib-gazyva versu chlorambucil-gazyva treatment-nav
cll patient candid fcr algorithm display exhibit control
arm studi altern b-r subject neither healthi fit
elderly/unfit repres substanti portion cll popul result
present simultan publish lancet day
median age enrol popul patient ecog
perform statu subject treat chlorambucil-gazyva receiv six cycl
treatment total i-g given six cycl follow ibrutinib monotherapi diseas
progress indefinit median follow-up time public month
time treatment on-going subject i-g arm
progress free surviv i-g statist superior c-g hazard ratio
exhibit estim month i-g c-g
advantag i-g also increas higher risk subpopul across
sub analys i-g arm better c-g
provid exclus use mari ellen eagan leerink pm
overal respons rate higher i-g compar c-g cr rate follow
trend vs mrd neg measur bone marrow subject
arm subject i-g arm mrd- bone marrow evalu compar
subject c-g arm anoth exampl need continu treatment
ibrutinib contain regimen order achiev surviv benefit versu
combin data allianc studi effect make
ibrutinib prefer regimen cll patient base respect trial comparison
patient popul physician interest result high
remark investig posit believ longer follow-up need
convinc cll doctor ibrutinib use major patient
long-term experi result fcr howev popul analysi suggest
ibrutinib could achiev closer penetr set next year
combin three studi suggest ibrutinib penetr incid cll patient could increas
toward within short time frame
obviou liabil ibrutinib set necess continu dose
progress recent interact treat physician indic strong interest
establish fix durat regimen includ ibrutinib cll addit
provid exclus use mari ellen eagan leerink pm
note earli surviv metric ibrutinib exceed chemoimmunotherapi
depth remiss ibrutinib alway superior potent chemo contain regimen
therefor discontinu rate ibrutinib relev like predictor longer-
term surviv outcom recent announc studi investig
month cours venclexta gazyva achiev superior versu chlorambucil-gazyva
primari endpoint studi present medic meet could
alter treatment landscap cll ad benefit rel short fix
great interest fix durat combo therapi induc deep remiss
phase ii studi conduct investig md anderson cancer center combin
ibrutinib fludarabin cyclophosphamid gazyva ifcg treatment-nav lower risk cll
patient show high rate mrd neg within first three month therapi
studi design base hypothesi mrd- rate standard care fcr could
improv base prior studi show improv mrd respons gazyva compar
rituxan addit ibrutinib standard care subject receiv ifcg cycl
follow ibrutinib-gazyva addit cycl either ibrutinib monotherapi
ibrutinib-gazyva addit cycl mrd- statu achiev exhibit essenc
total exposur chemotherapi fc reduc standard cycl
outcom base protocol place defin durat combin treatment follow
total cycl ibrutinib subject mrd- point continu ibrutinib
indefinit still evid diseas bone marrow continu
tradit treatment progress protocol studi design investig whether
potent up-front combin treatment could erad sign diseas allow fix
durat treatment treatment nave cll patient current chemo contain regimen
fix treatment durat ibrutinib gener taken indefinit period time
provid exclus use mari ellen eagan leerink pm
total subject complet least cycl ifcg part studi analysi
overal respons rate achiev cr/cri percentag subject
undetect diseas bone marrow cycl mrd- improv
month month prior studi fcr shown mrd- rate
cycl total cycl suggest ifcg regimen much
effect complet erad leukem cell bodi exhibit
provid exclus use mari ellen eagan leerink pm
exhibit ifcg result unpreced level mrd neg
subject month follow-up achiev mrd- statu patient remain
ibrutinib beyond time howev patient continu follow post-ibrutinib discontinu
data cutoff patient shown sign clinic diseas mrd month
median follow-up time ifcg regimen appear reason well toler small
dataset grade neutropenia thrombocytopenia occur subject dose
reduct took place ibrutinib subject fc
small single-cent trial data potenti transform
treatment indic result confirm larger random phase studi
cr/cri mrd- rate appear higher end substanti
demonstr compar frontlin trial fcr ibrutinib alon assum durabl
deep respons expect one would assum clear surviv advantag would occur
ifcg regimen unlik abbvie/jnj would ever want conduct studi
registr purpos sinc fix durat ibrutinib would econom disadvantag
compani alreadi wealth data encourag adopt ibrutinib
across treatment-nav popul
investig md anderson cancer center also present data anoth phase ii studi
evalu ibrutinib venclexta treatment-nav high risk cll patient subject
studi least one high risk featur base enrol criteria patient
studi receiv month run-in ibrutinib monotherapi prior start venclexta dose
provid exclus use mari ellen eagan leerink pm
escal receiv continu dose agent month median age
studi popul year subject high risk featur unmut ighv
mutat
month treatment month combin patient respons
cr/cri mrd- bone marrow investig respons continu
deepen time month combin treatment cr/cri mrd-
rate improv exhibit combin ibrutinib-venclexta thought
addit effect deepen respons erad bone marrow diseas sinc two agent
uniqu mechan action non-overlap median follow-up
month present subject cll progress yet
exhibit i-v seem potent high rate mrd neg
potenti concern combin ibrutinib-venclexta addit toxic howev toxic
profil two agent minim overlap run-in treatment period ibrutinib
quit effect reduc risk tumor lysi syndrom due venclexta grade
toxic appear similar expect either agent alon rate
neutropenia rate thrombocytopenia three subject laboratori evid tumor
lysi syndrom although none show clinic symptom dose reduct ibrutinib occur
subject commonli due atrial fibril neutropenia venclexta requir dose
reduct subject
provid exclus use mari ellen eagan leerink pm
addit follow-up studi need determin whether month fix durat
regimen i-v inde feasibl result good long-term surviv outcom base
deep respons high mrd- rate assum outcom would show improv durabl
current treatment option physician could potenti resum one agent
first evid bone marrow diseas activ
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg sni averag consensu ep
multipl appli current ep estim give valu
use revenu multipl similar compani consensu
sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
provid exclus use mari ellen eagan leerink pm
million
leerink partner research compani file
provid exclus use mari ellen eagan leerink pm
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
provid exclus use mari ellen eagan leerink pm
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
provid exclus use mari ellen eagan leerink pm
reason report
updat suggest tibsovo signific role aml
bottom line agio present updat tibsovo
frontlin acut myeloid leukemia aml american societi
hematolog meet view posit
mitig recent investor pessim class
share pressur monday result believ highli
competit venclexta combo data combin weak idhifa
dataset safeti concern rais question frontlin idh
monotherapi treatment patient elig
standard regimen tibsovo highli activ manag
safeti profil set accur reflect
develop path treatment paradigm sunday
idhi chemo produc deep highli durabl remiss
abstract present phase result combin either
tibsovo idhifa standard induct chemo untreat aml
patient enrol patient receiv idh inhibitor combin
induct consolid chemo singl agent idh inhibitor
mainten option follow consolid patient
elig receiv mainten cr cri/crp tibsovo
patient de novo aml secondari aml
idhifa cohort de novo secondari diseas
respect minimum residu diseas mrd neg achiev
tibsovo patient cr/cri/crp
analog idhifa patient importantli os tibsovo
patient idhifa patient median yet reach either
cohort see durabl impress given diseas set
idhi regimen well toler frontlin patient ad
idh inhibitor result unaccept toxic treatment
relat mortal mortal tibsovo
idhifa arm mortal respect trial
death occur tibsovo patient idhifa patient
discontinu due advers event seen
tibsovo patient patient idhifa arm interestingli
differenti syndrom ds seen tibsovo patient
idhifa patient potenti due chemo-induc cytoreduct
see data valid combin agent
chemo particularli combin deep durabl activ
consid agio celgen celg op support
phase hovon aml cooper trial test regimen
frontlin aml trial initi expect
tibsovo monotherapi offer compel altern patient
elig standard treatment abstract highlight tibsovo
monotherapi frontlin aml patient elig receiv standard
patient enrol trial poor prognosi patient
present secondari aml receiv prior hma
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
previou heme malign patient older
patient intermedi cytogenet risk poor risk
statu orr cr/crh impress given
lack option patient median durat treatment
median overal surviv follow-
interestingli median durat respons reach
sever respond remain treatment well beyond month
repres signific benefit patient view treatment
well toler low incid grade higher ds
observ patient patient case
grade higher patient dose delay due ds
none dose reduct discontinu treatment ds resolv
patient observ see data compel
given durabl respons produc toler regimen patient
without therapeut option agio intend submit dataset
snda tibsovo
despit competit see role idh inhibit aml
pressur share driven larg competit concern
venclexta resurg safeti concern due ds view
although see venclexta signific competitor believ
data present monday repair lost physician
investor enthusiasm idh class aml
provid exclus use mari ellen eagan leerink pm
reason report
competit idh safeti concern could pressur
bottom line present american societi hematolog
annual meet weekend highlight updat
dataset treatment-nav acut myeloid leukemia aml includ
combo inhibitor venclexta regimen produc
robust activ particularli patient mutat
exceed singl agent activ idhifa partner celg
op frontlin aml present session addit
fda deliv present meet regard
safeti commun differenti syndrom seen idh
inhibitor includ result safeti meta-analysi
session lead physician meet question
use idh inhibitor least singl agent frontlin therapi
aml although believ result idhifa dataset
repres frontlin use class see potenti
pressur share given increas percept
competit venclexta linger safeti concern
venclexta combo highli activ especi idhm patient
abstract featur venclexta combin low dose cytarabin
older untreat aml patient duo produc cr/cri rate
patient similarli venclexta hma
vidaza dacogen result cr/cri overal cohort
patient minimum residu diseas
neg mrd- seen patient low dose cytarabin
receiv vidaza dacogen arm
idhifa monotherapi fall short relev regimen unclear
abstract present earli result cohort
aml master trial precis medicin basket trial run
leukemia lymphoma societi cr/cri compar unfavor
activ idhm patient seen either venclexta combo co-
occurr ra mutat neg indic idhifa activ
unclear patient respond venclexta regimen
importantli relev singl agent idhifa cohort unclear
us given frontlin develop plan idhifa tibsovo
reli hma chemo combo least patient abl receiv
combo therapi activ venclexta combo
superl idhm patient would expect substanti improv
activ idhifa/tibsovo combin
differenti syndrom warn emphas safeti
present last week fda issu safeti commun
ae idh inhibitor fda believ suffici
monitor physician see meet fda investig
present result safeti meta-analysi perform ds
includ differ regul trial investig
adjud although ds new find idhifa tibsovo
contain black box warn rate adjud fda higher
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
trial investig may surpris physician
like pressur increas percept
competit physician skeptic see share
like pressur given concern idh inhibitor use frontlin
aml doctor meet express skeptic use
agent particular idhifa frontlin aml given percept
diminish activ compar venclexta resurg concern
ds view idhifa monotherapi data present meet
repres accur assess idh inhibitor develop
plan opportun relev view updat
present idhifa tibsovo combin frontlin
induct local time tibsovo monotherapi frontlin
patient elig therapi local time
howev clear venclexta repres signific competitor
physician enthusiasm idh class appear impair potenti
challeng frontlin uptak like pressur share view
provid exclus use mari ellen eagan leerink pm
reason report
bottom line yesterday investig present final
result second two pivot trial alexion ravulizumab
rav previous known soon known
ultomiri compani previous present first efficaci
result european hematolog meet june pivot
switch trial also use current label dose soliri control
arm weekli even though patient reportedli
stabl well control dose soliri mani patient requir
higher dose stabil condit comparison investig
dose ravulizumab load
week achiev much complet consist target inhibit
higher plasma exposur
roch much anticip present confirm
mani best featur rav albeit half-lif
long ravulizumab mean best day
could administ monthli two weekli schedul vs
weekli dose rav hand clear formul
suitabl iv sc administr expect
studi pivot trial isnt suggest
take market antibodi like
drug least part market product within
year approv
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
provid exclus use emili singletari leerink pm
price target rate stock
outperform alexion lead independ compani develop commerci
treatment ultra-rar disord complement system nineti percent revenu
today come soliri approv two differ rare diseas indic
believ alexion increas current revenu run rate complement franchis
competit threat soliri overst view given long safeti
efficaci histori soliri well alexion progress develop improv version
product greater potenc longer half-lif conveni dose beyond soliri
alexion still earli phase launch two addit rare diseas medicin
kanuma strensiq expect contribut approxim combin revenu
alexion maintain reason financi disciplin expect oper
margin bounc back better drop
acquisit synageva cost two product launch
alexion remain one fastest grow busi biopharmaceut durabl
larg molecul protein therapi believ recov multipl come quarter
fail trade discount reason cautiou outlook could becom
one target expect increasingli consolid industri
pnh switch data highlight
oral present pivot trial rav kulasekararaj et al investig present
result switch trial patient pnh paroxysm nocturn hemoglobinuria
alreadi stabl eculizumab soliri studi enrol patient
treat ravulizumab soliri treatment continu week
patient enrol open-label extens studi ole patient
enrol trial fairli typic pnh patient mostli european asian studi
site averag age averag durat prior treatment soliri
year patient receiv transfus prior year pnh
diagnos approxim year
primari endpoint non-inferior soliri percentag chang lactat
dehydrogenas ldh percentag chang ldh higher ravulizumab treat
patient compar soliri differ right verg statist signific
superior rav easili met threshold non-inferior
secondari endpoint breakthrough hemolysi chang facit fatigu score transfus
avoid hemoglobin stabil rav also non-inferior eculizumab actual
result endpoint favor ravulizumab numer achiev statist
signific lower confid interv secondari endpoint cross
substanti higher margin non-inferior remind
prior impress result alexion recruit patient
confid interv might tighten confer statist superior one
endpoint
present show ldh level kept limit normal almost time
point rav wherea median upper limit confid interv soliri well
uln upper level normal impress free level rav treat patient
effect flat complet inhibit comparison level free soliris-
treat patient fluctuat rel wide treatment period consist
effect complet inhibit seen seen trial safeti outcom
similar two arm increas advers event ae seriou
treatment emerg infect death event patient given rav
somewhat upper respiratori tract infect rav treat patient vs
headach well less cough
accompani pk/pd analysi two pivot trial alexion show
ravulizumab cmax consist across differ size patient two trial
declin trough plasma concentr higher bodi weight cumul
serum concentr area curv exposur substanti higher rav
soliri point studi observ period week serum drug
concentr rav drop soliri plasma concentr time point
provid exclus use emili singletari leerink pm
rav treat patient total serum level slightli lower soliri treat
patient case stabl throughout treatment free concentr
comparison two group inform mani case breakthrough
increas soliri treat patient compar liter increas rav
treat patient result similar nave experienc
pivot trial ravulizumab achiev complet effect perman suppress
wherea breakthrough increas common soliri least standard label
final alexion also present result sub group analysi treatment-nav pivot
trial ravulizumab surprisingli sub group analysi trial mean result
gener favor ravulizumab although lower bound confid interv cross zero
everi case endpoint transfus avoid subgroup numer
favor soliri small number patient enrol north america comparison
larger cohort enrol europ asia pacif japan latin america mean
favor rav soliri ldh normal endpoint variat
result although trend also gener favor rav result ldh percent chang
baselin fatigu score breakthrough result also gener consist across
subgroup overal breakthrough hemolysi rate numer lower rav treat patient
although endpoint result miss statist signific
total result suggest ravulizumab superior label dose soliri though
clear would fare typic increas week dose even without
superior physician patient probabl regul go recogn benefit
complet complement suppress offer ravulizumab patient treat sever
diseas soliri approv hard see physician patient
choos remain soliri face pharmacolog advantag even
consid benefit reduct number infus presum compar
price exist soliri
look activ suitabl self administr
meet investig present earli clinic result roch much anticip
antibodi patient pnh engin antibodi similar
half-lif enhanc alexion specif design
long act also suitabl self sc administr investig present
result compani intra-pati dose escal eculizumab nave pnh patient
preliminari result prior soliri treatment present highlight
plasma concentr weekli dose sc weekli two weekli
weekli monthli dose sc monthli initi escal iv load dose
dose test appear maintain plasma concentr target trough
level although exposur highest treatment nave patient treat weekli sc
inject roch disclos termin half-lif estim day approxim half
half-lif alexion ravulizumab disclos present day
treatment nave patient activ pnh reduc ldh uln
appear patient similarli free concentr fell nearli undetect
level cohort remain low level throughout day observ period
switch patient ldh level maintain rang uln
free concentr also appear reach effect undetect level
treat patient compar baselin level soliri reduc total
includ bound approxim although treatment nave pnh patient total level
also increas rang time
sinc bind differ epitop soliri rav roch assert
also block complement activ hemolysi patient rel rare missens
mutat confer resist soliri roch report patient
reduct hemolysi soliri treatment wherea patient respons
similar patient lack mutat roch also present hb respons
treatment soliri respons good day treatment nave
patient occur switch patient despit treatment patient continu
provid exclus use emili singletari leerink pm
seem reason well toler rel moder advers event safeti
complaint rash evid increas infect risk liabil might
also relat develop drug-target-drug antibodi immun complex roch
realiz previous treat patient introduc drug care
slowli order avoid trigger form serum sick immun reaction
skin reaction occur patient switch trial
overal clear effect rel safe complement antibodi
seem like given two weekli monthli schedul certainli superior
soliri fall short ravulizumab howev could advantag sc self-
administr inde compani get pivot trial either two weekli sc
monthli sc schedul efficaci encourag posit seem
superior reason dont see nich immedi occupi
still enrol complet pivot trial lead indic remain sever
year market longer term drug market impact soliri alexion depend
data trial ultim label grant roch fda
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use
termin growth rate post give current valu averag
three valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
provid exclus use emili singletari leerink pm
million
leerink partner research compani file
provid exclus use emili singletari leerink pm
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
provid exclus use emili singletari leerink pm
analysi stock price leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
leerink estimate earn
current averag larg cap biopharma multipl ep
leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co celg
impli ep multipl discount vs full multipl
averag method
leerink partner research compani file factset
provid exclus use emili singletari leerink pm
reason report
bottom line updat data arql phase dose-escal
studi arq revers inhibitor wild type
mutant btk relapsed/refractori hematolog malign
present american societi hematolog
notabl present highlight initi clinic
data therapeut dose arq overal view data
still earli posit takeaway includ increas anti-tumor
activ observ increas dose good safeti profil support
continu dose escal one patient continu studi
month partial respons pr achiev patient follicular
lymphoma fl investor may disappoint lack
respons achiev patient chronic lymphocyt leukemia
cll preliminari data would emphas cll
patient treat highest dose cohort cohort achiev
tumor reduct scan time addit
cll patient heavili pretreat median prior therapi
repres sicker patient popul arql intend patient
popul ultim data patient treat highest dose
cohort cohort avail consist prior
manag guidanc competitor data snss vecabrutinib also
revers btk inhibitor also present highlight
preliminari safeti pharmacolog data cll
landscap remain dynam competit medacorp kol
check highlight potenti arq link continu see
potenti long-term appreci arq becom de-risk
arq phase dose-escal data still earli recal phase
dose-escal studi arq relapsed/refractori hematolog
malign evalu arq across dose cohort
patient expect approach therapeut dose cohort
qd qd efficaci data patient cohort
qd avail in-lin previou guidanc though
respons observ defin tumor reduct
cll data present indic clear benefit increas
dose patient cll patient treat cohort
demonstr tumor reduct first scan addit
patient treat non-hodgkin lymphoma nhl
receiv btk-inhibitor one patient partial respons pr
three patient stabl diseas sd signific tumor reduct
total patient cll patient mutat stabl
diseas includ tumor reduct
safeti profil continu look good safeti profil observ
dose cohort support continu dose escal
dose-limit toxic observ patient experienc seriou
advers event sae none deem drug-rel
manag previous indic possibl dose-escal
beyond cohort order determin maximum-toler dose
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
arql host call discuss result today estimate
competitor snss data demonstr earli safeti
pharmacolog data snss present data phase ib/ii
dose escal studi vecabrutinib patient advanc cell
malign snss also host analyst investor event
includ perspect investig vecabrutinib
profil phase data highlight potenti commerci
opportun refractori cll patient mutat dose
escal remain on-going snss guid toward target dose level
twice daili bid
provid exclus use mari ellen eagan leerink pm
reason report
data earli multipl readout
bottom line initi data asln phase iia studi
dhodh inhibitor acut myeloid leukemia aml patient inelig
standard treatment present american societi
hematolog overal data earli
intrigu evalu patient data cut-off show
sign activ although complet respons cr achiev
evalu monotherapi continu asln
ad expans arm evalu combin
azacitidin repres upsid current estim
competitor dhodh space includ bayer
current phase studi myeloid malign agio mp
ind submit also spoke asln manag
highlight data well multipl upcom data
readout lead program varlitinib recal asln oncology-
focus biopharmaceut compani base singapor develop
therapeut global market compani lead program varlitinib
pan-her inhibitor target recal
varlitinib origin licens arri complet
five phase studi rang solid tumor asln develop
varlitinib indic high preval asia includ biliari tract
cancer gastric cancer varlitinib clinic data gener
date asln arri demonstr activ want
see clinic mechanist valid varlitinib given biliari
tract cancer histor difficult space drug develop
mechanist advantag varlitinib pan-her inhibitor
remain unclear given implic target remain poorli
understood overal posit asln asia-focus
develop strategi experi manag team
would want see clinic mechanist valid varlitinib
earli data demonstr intrigu sign activ
phase iia studi evalu dhodh inhibitor r/r
aml four dose cohort qd qd
day bid bid aml patient inelig
standard treatment includ relaps refractori treatment
nave enrol evalu efficaci
patient evalu efficaci show sign clinic efficaci
patient qd qd exhibit evid
myeloid differenti patient qd develop suspect
differenti syndrom notabl patient stabl diseas
month data indic improv vs abstract
disclos total patient demonstr earli signal
clinic activ notabl evalu patient includ
receiv least one post-treat assess cutoff date
patient report abstract includ
patient treat cutoff date previous
phase singl multipl ascend dose studi demonstr
dose proport pharmacokinet accumul well-
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
toler safeti profil healthi subject maximum dose
mg daili
preclin present asln
second present highlight effect
cell growth differenti apoptosi gene express
chang aml cell line primari bone marrow cell aml
manag convers highlight data well
upcom catalyst manag view differenti
syndrom ds observ earli data patient
posit signal activ see ds barrier bring
market asln form committe review case
note investig look addit
expans cohort evalu combin
azacitidin ad manag continu see potenti
monotherapi pk model suggest respons
could achiev bid dose cohort
multipl data readout top-lin data treetopp
studi still expect recal treetopp phase
ii random double-blind studi varlitinib combin
capecitabin patient advanc metastat biliari tract cancer
near-term catalyst includ top-lin data global phase ii/
studi varlitinib folfox co-express line
gastric cancer like earli interim readout phase i/
ii studi varlitinib gemcitabin cisplatin line biliari tract cancer
gi abstract pool analysi three phase
studi varlitinib combin platinum-bas regimen biliari
tract cancer also present gi abstract
provid exclus use mari ellen eagan leerink pm
reason report
zanubrutinib updat mcl re-affirm differenti
bottom line beigen present two updat zanubrutinib
mantl cell lymphoma mcl continu support
drug promis differenti safeti activ
american societi hematolog pivot mcl data
china present oral present follow poster
review data global phase trial pivot china
trial zanubrutinib show broad deep activ object
respons rate orr complet respons cr rate
appear superior imbruvica calquenc importantli
safeti trial continu look differenti low bleed
rate atrial fibril activ zanubrutinib continu
compel believ maintain safeti toler
differenti key zanubrutinib use market
bgne invest thesi given imbruvica well-entrench
pivot china trial patient enrol patient
receiv median prior line therapi rang
refractori prior treatment orr assess independ
review cr subgroup analysi show littl impact
orr ecog statu number prior line presenc bulki
blastoid diseas proport diseas stage studi entri
sub-analysi show impact orr older
patient appear perform wors disclos abstract
respond event free week overal progression-fre
surviv week week howev
signific censor suggest data matur pet-ct
scan perform patient pet evalu diseas
patient discontinu due treatment emerg advers event teae
six patient die within day last treatment includ four due
teae importantli one patient major hemorrhag
patient trial experienc atrial fibrillation/flutt view
safeti profil drug rel imbruvica calquenc key
differenti factor shape expect regard commerci
potenti drug western market
durabl respons seen global phase global phase
trial mcl patient enrol median prior line therapi
rang patient treatment nave orr assess
investig cr rate respons
primarili assess ct contrast china phase trial
may contribut lower cr rate ct scan
confound scar tumor regress versu pet scan
measur metabol activ median progression-fre surviv
mpf cohort month suggest impress durabl
eight patient discontinu due teae three die
common grade higher teae anemia cellul
pneumonia myalgia neutropenia note atrial
fibrillation/flutt seen two patient three patient
major hemorrhag
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
zanubrutinib appear superior market leader view
current updat highli promis compar expect perform
imbruvica calquenc set base prescrib
inform orr imbruvica r/r mcl cr
wherea orr calquenc cr zanubrutinib
produc deeper respons pivot china trial given higher
orr orr investor question lower
cr rate global phase despit high orr note
trial enrol heterogen phase cohort importantli
mandat pet-ct scan respons evalu contrast
china trial pet scan standard evalu mcl
accur ct scan alon metabol dead scar tissu
appear like persist lesion ct scan despit lower cr rate
patient treat phase demonstr mpf
show impress durabl given median durat respons
imbruvica set
zanubrutinib safeti differenti support vitro data
meet although zanubrutinib shown compel activ
rang set believ maintain differenti safeti profil
key particularli upcom head-to-head data set zanubrutinib
imbruvica waldenstrom pre-clin evid
bleed zanubrutinib compar imbruvica
inhibit profil appear optim btk target spare
kinas investor question whether
zanubrutinib fact differenti profil note exampl
patient phase atrial fibril see
drug continu show lower rate classic btk tox dataset
overal clinic experi note long term follow-up data
calquenc mcl show patient cardiac
grade event rate toxic appear greater
sever seen zanubrutinib
provid exclus use mari ellen eagan leerink pm
reason report
ahead pack competit still chase bcma
bottom line competit bcma space increas
stand-out therapi immedi threat blue lead candid
emerg year confer continu
believ retain sizabl lead anti-bcma car-t therapi
could rais bar even time competitor
readi pivot data first-gener product review
bcma data date exhibit page elsewher pipelin
op present encourag data transfusion-depend
thalassemia patient studi readout
impress group data sickl cell diseas scd
encourag data lentiglobin treatment -thalassemia
scd last night present data phase
studi lentiglobin transfusion-depend -thalassemia
data cutoff three patient display total
hemoglobin express least g/dl level could support
transfus independ one patient transfusion-fre
administr lentiglobin second patient last transfus
month post-treat month follow-up
third patient last transfus month post-lentiglobin
administr three month follow-up though data earli
quick ramp promis patient
show increas hemoglobin express month post-
lentiglobin administr though long-term follow-up need
better understand durabl patient updat result
least month follow-up rang month
patient maintain transfusion-independ increas
patient previou data cutoff patient also display
total hemoglobin level g/dl express
g/dl result appear in-lin result observ
studi overal northstar studi show promis level
hemoglobin express worri safeti signal detect
studi group patient scd calm
investor nervous case myelodysplast syndrom md
disclos studi see previou note combin
attract safeti data show encourag
patient least anti-sickl hb month
timepoint
compet car-t therapi make progress
maintain compel clinic profil sizabl lead clinic
year present featur readout compet car-
legend bi-specif bite therapi mp result
dose escal phase phase i/ii evolv trial
patient treat three dose level overal median follow-
time short week overal respons rate orr
among patient patient treat lowest dose
cr rate decent given low dose short follow-up
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
toler in-lin expect patient
grade patient show
sign neurotox grade believ
could potenti show similar safety/efficaci profil dose
potenti approv gener improv
could obsolet reach pivot data
data jnj appear promis orr
cr rate median though data much
less sever patient car-t therapi
evalu patient median previou
line therapi lcar evalu patient median
prior line therapi thu lcar patient less advanc diseas
baselin cr rate durat respons may inflat vs
bcma car-t due differ baselin characterist
earli data interest competitor
view phase dose escal studi
identifi ug/day maximum-toler dose move
forward though patient treat dose result
promis patient respond treatment orr
patient mrd-neg complet respons though
note patient median prior line therapi fewer
patient car-t studi dont believ would
directli compet mp manag discuss
three potenti patient segment use includ rapidli
progress patient take advantag off-the-shelf natur
patient inelig car-t patient earlier
line treatment segment would like candid
immedi approv phase ib trial schedul
initi
efficaci in-lin earli assess durat
respons phase dose escal studi blue
follow-on featur earlier poster present
dose escal began cells/pati lowest efficaci
dose test karmma studi patient receiv
patient respond treatment
vgpr pr on-going respons patient eight
patient treat develop half
grade patient experienc neurotox though
one grade case safeti signal also seen one
patient karmma dose escal orr numer higher
orr achiev karmma though patient
number still low await data readout assess
potenti durat respons patient util
refin manufactur process aim creat durabl t-cell
may potenti show longer-liv respons median
seen karmma studi
provid exclus use mari ellen eagan leerink pm
exhibit anti-bcma efficaci safeti data updat
compani present present orr overal respons rate scr/cr stringent complet response/complet respons vgpr good partial respons
pr partial respons nr report
provid exclus use mari ellen eagan leerink pm
companyblue/celgblue/celgnncelgjnj nanj dose subject activ monthsani prior line stat
reason report
bottom line updat data phase explor trial
avapritinib advanc system mastocytosi asm present
american societi hematolog meet weekend
respons avapritinib continu broad deep highli
durabl blueprint detail result new patient report outcom
questionnair demonstr treatment associ
signific reduct symptom asm well improv
qualiti life patient indol sm enrol current
trial experienc signific reduct mast cell burden key
demonstr activ less sever patient expect
translat symptomat relief reiter outperform rate
believ bpmc avapritinib like captur major sm
opportun mirror unpreced activ also seen pdgfra
gastrointestin stromal tumor gist rel competitor
deep durabl respons translat symptomat relief
object respons avapritinib cr/crh modifi
iwg-mrt-ecnm criteria median durat respons dor
reach respons on-going month
median follow-up dor addit
durabl respons deepen time patient median
time initi respons month median time reach
cr/crh month note patient receiv lower
qd dose object respons rate orr indic
wide therapeut window room optim toler without
compromis activ key factor indol popul
symptom-relief paramount
demonstr symptomat improv valid
approach ism/ssm blueprint present result advsm-saf
advanc sm-symptom assess novel design
track burden sm symptom advsm-saf cover symptom
relat gi skin morbid addit fatigu composit
total symptom score tss calcul tss fell averag
baselin patient bothersom symptom fell
treatment support find reduc symptom
burden patient decreas steroid dose studi
discontinu entir compani creat differ
indol diseas could incorpor metric
avapritinib toler remain good like improv
dose optim major advers event patient
avapritinib patient experienc grade
higher ae discontinu due treatment relat
ascit encephalopathi intracrani bleed patient remain
treatment cognit effect seen
robust activ indolent/smold patient
discontinu even dose expect use
subsequ trial includ updat patient ism/
ssm saw robust improv variou measur mast
pleas refer page import disclosur price chart analyst certif
provid exclus use mari ellen eagan leerink pm
cell burden broad activ seen patient reminisc
earli data releas advanc set translat
symptomat improv key uptak indol set
importantli patient on-going treatment median
durat suggest drug toler even dose
could exceed go forward dose time given blueprint
consid dose mg daili set
recent grant breakthrough therapi design sm suggest
count yet neg investor sentiment
regard competit profil loxo op
headwind share addit direct percept
regard data mani investor seen fda btd grant
without similar action confirm
lead statu howev believ may reflect
differ develop regulatori strategi fundament
differ drug note announc breakthrough
therapi design btd statu avapritinib asm end
octob drug featur plenari
session view histor priorit regulatori align
develop path seek design btd
suggest could yet receiv btd believ btd
design could signific catalyst share
face investor skeptic program
provid exclus use mari ellen eagan leerink pm
reason report
could drd treatment what month
myeloma
bottom line american societi hematolog
week jnj op maia trial show remark efficaci
daratumumab-revlimid lenalidomid -dexamethason
drd treatment compar revlimid lenalidomid
dexamethason rd transplant inelig newli diagnos
myeloma patient publish week maia late breaker
data present suggest drd potenti displac
current velcade-revlimid-dexamethason vrd gold standard
treatment frontlin myeloma transplant-inelig patient
median drd frontlin myeloma seem like extend
beyond month offer tantal prospect durabl
remiss signific number patient howev studi
present recent meet shown import
continu mainten treatment myeloma even initi induct
requir continu treatment dramat increas
per regimen cost drd estim year drd cost
approxim drug cost drd assum median
treatment durat month like pose
major barrier adopt mani part world
popul us progression-fre surviv ultim
exce month total drug cost singl regimen
could surpass us
outsid us drug price like lower
us rel cost valu argument
regimen still like occur high singl line treatment
cost make great financi target valu emerg one-tim
treatment bcma car-t could potenti achiev
similar outcom payer physician patient could prefer novel
combin strategi design induc deep respons rel
short durat regimen allow extend treatment-fre
interv potenti re-treat recurr base highli
sensit surveil year saw mani present
novel multi-drug combin could potenti use
averag method dcf price
earn price sale
net debt total capit
price-to-earnings lt ep growth
per share per share end
year price history/av daili volume mil celg
compani inform leerink partner llc research
revenu million ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
provid exclus use mari ellen eagan leerink pm
estim total regimen treatment cost approv
recommend recent studi regimen non-transpl
frontlin myeloma set us use clinic trial protocol
progression-free-surviv median treatment durat pivot
trial price databas separ estim cost
induct month consolid month mainten
month cost induct treatment similar drd
vrd cost differ regimen tend
diverg month consolid differ
becom much greater cost mainten includ
estim total regimen cost drd significantli
d-vmp vrd take progression-
free surviv account total regimen cost drd becom
accept per month compar velcade-
melphalan-prednison vmp compar rd
compar vrd inde yesterday kol mention us
cost drd trivial take progression-fre surviv benefit
account treatment premium patient popul drd
worth believ drd rapidli adopt
thu cost drd inevit expens signific
benefit shown drd rais barrier entri new indic
frontlin myeloma drd combin like
becom new standard care regimen non-transplant-elig
provid exclus use mari ellen eagan leerink pm
price target celgen corp celg stock rate outperform celgen
transform treatment one form cancer myeloma aim transform
treatment other futur core technolog develop small molecul
drug base chemistri immunomodulatori drug imid form variant
thalidomid drug proven tremend effect myeloma today
compani gener annual revenu hematolog product sale almost
myeloma imid product franchis continu grow volume-limit
gener revlimid entri given structur characterist market posit
myeloma beyond imid celgen invest right broad array novel technolog
product hematolog oncolog inflammatori diseas potenti
product remain seen shape critic year assess valu
like return invest
treatment drd outperform frontlin myeloma treatment regimen
compar data frontlin set maia alcyon swog trial
drd data look impress exhibit median reach drd arm
compar month rd arm importantli drd data look better d-vmp
also yet reach median updat data present year show
rate month d-vmp arm alcyon trial abstract
swog studi vrd arm achiev median month control arm rd
similar maia studi median month control rd arm
treatment outperform vmp treatment arm median
month recent research see link compar kaplan-mei
surviv curv differ frontlin non-transpl myeloma regimen suggest drd
best ever seen base earli sustain respons
provid exclus use mari ellen eagan leerink pm
exhibit comparison progression-fre surviv frontlin myeloma therapi
median d-vmp drd arm estim month
estim total drug cost frontlin myeloma therapi assum continu
treatment regimen median reach unless treatment fix durat
median frontlin treatment regimen reach swog median
vrd arm month trial median vmp arm month
estim median d-vmp arm similar vrd arm swog
trial month exhibit d-vmp vrd arm base alcyon updat
abstract disclos median reach month
rate estim median drd arm maia trial extrapol
month present week expect median reach
approxim month also look updat result second line pollux
trial disclos year abstract drd arm
estim pollux trial month activ arm maia appear
perform even better activ arm pollux trial exhibit estim
drd arm maia trial around month exhibit
provid exclus use mari ellen eagan leerink pm
exhibit comparison drd activ arm maia pollux
exhibit median estim median frontlin myeloma therapi
induct cost similar frontlin regimen diverg longer treatment
estim frontlin total regimen drug cost obtain net drug price inform
medicar part drug averag sale price file calcul cost per
treatment cycl base studi protocol note presum treatment time
correspond median reach regimen treatment progress
label full durat treatment fix durat regimen cost first three
month induct treatment rel similar vrd d-vmp
drd exhibit cost treatment start separ period
month vrd d-vmp drd significantli differ
cost period estim revlimid compon alon cost per
treatment cycl per year inde frontlin treatment rd estim cost
first month cost consolid month
provid exclus use mari ellen eagan leerink pm
-free surviv time month activ arm drd maia activ arm drd pollux median estim month rdrevlimid melphalan myeloma celgen corpor
cost mainten treatment vari even wide depend drug use
mainten manner standard protocol exampl rd vrd drd revlimid
dexamethason continu progress cost drd
regimen cost mainten increas addit cost darzalex
underli rd cost mainten cost d-vmp regimen start month first
treatment onward estim median month estim rel modest
sinc mainten regimen consist darzalex corticosteroid
d-vmp vmp stop cycl follow treatment daratumumab
dexamethason progress estim month rd
estim mainten cost vrd mainten
medicin use set revlimid/low dose dexamethason
durat significantli longer vrd cost mainten therapi drd
significantli higher frontlin regimen due long durat mainten
treatment combin cost rd daratumumab estim cost cycl
per month exhibit take account mainten treatment frontlin
regimen median estim total regimen cost significantli expens
drd compar d-vmp vrd exhibit
monthli mainten cost per month median drd reach month
rather month estim analysi total treatment drug cost would
exhibit estim induct consolid mainten cost frontlin
leerink research estim center medicar medicaid part averag sale price price rx san
provid exclus use mari ellen eagan leerink pm
costcost induct monthscost consolid monthscost maintain month median celgen corpor
exhibit total estim cost frontlin myeloma treatment regimen
leerink research estim center medicar medicaid part averag sale price price rx san
drd larg valu may line given efficaci
total treatment regimen cost significantli higher drd compar frontlin
therapeut total regimen cost drd vmp
rd vrd exhibit cost premia may justifi
increment benefit depend context differ regimen regimen cost
per month drd vmp rd d-vmp
thu total cours treatment drd cost per month
vmp drd cost per month compar d-vmp yet
compar total regimen cost per month drd rd vrd drd cost
per month rd per month vrd exhibit
exhibit comparison cost per month frontlin myeloma treatment
leerink research estim center medicar medicaid part averag sale price price rx san
provid exclus use mari ellen eagan leerink pm
total regimen median estim month per month rdrevlimid melphalan myeloma regimen celgen corpor
exhibit cost per month frontlin myeloma treatment regimen
leerink research estim center medicar medicaid part averag sale price price rx san
understand rel clinic benefit cost differ treatment option
frontlin myeloma evalu addit cost treatment per addit month
compar variou benchmark lowest cost regimen today vmp mp rare
use us word analysi calcul increas total regimen cost
compar refer regimen calcul increas compar
refer regimen give us increment cost per increment month
differ state-of-the-art regimen analyz treatment regimen analysi
benefit one treatment regimen anoth differ
treatment regimen exampl drd highest estim median
month none treatment regimen posit chang compar
drd
compar vmp cost per addit month drd
rd exhibit compar rd increment cost per addit month
vrd per increment month drd exhibit previous
mention note key advantag rd vmp drd d-vmp
appear abil achiev long durat treatment sinc clear myeloma
possibl malign well maintain continu pressur tumor result
better long-term outcom tradit intermitt treatment cours
provid exclus use mari ellen eagan leerink pm
exhibit comparison increment regimen cost per increment month
frontlin myeloma regimen
leerink research estim center medicar medicaid part averag sale price price rx san
provid exclus use mari ellen eagan leerink pm
price target celgen celg base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg cap medic product drug devic
compani present valu base price sale multipl peer coverag
discount cash flow dcf analysi use averag peer mature/end patent life larg cap
biopharma compani multipl consensu ep appli
ep estim celgen support one-year price target use exclus
matur biopharma rhhbi price sale multipl
revenu appli revenu estim give fair valu lastli
dcf use estim compani current wacc appli period cash
flow assum annual declin cash flow termin valu
adjust cash debt give present valu per share averag
three approach current price target
risk view outlook valuat celgen includ major chang price
reimburs coverag revlimid compani main product today risk includ
commerci develop disappoint compani diversifi program otezla
ozanimod lastli challeng compani revlimid patent posit would
view neg investor would larg dilut acquisit research invest
could undermin compani oper profit return invest capit
opportun greater upsid current forecast includ duplic earli clinic trial
result ozanimod expand trial inflammatori bowel diseas success develop
commerci program compani collabor bluebird
earli impress result acceler develop compani
antibodi tislelizumab partner beigen bgne
provid exclus use mari ellen eagan leerink pm
otezla apremilast po adjust indic dev
million
vidaza pharmion mid march
leerink partner research compani file
provid exclus use mari ellen eagan leerink pm
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
provid exclus use mari ellen eagan leerink pm
analysi stock price leerink target celgen
method price base mature/end patent life larg cap biopharma ep multipl
appli celg ep
leerink forma ep estim celg
price
equiti
number period
method present valu base price sale multipl matur larg cap biopharma
averag price sale larg cap biopharma multipl
impli celg market cap estimate sale
anticip share count mm
number period
method leerink probabl adjust dcf adjust net wacc cash
averag method
sourc leerink partner estim compani file factset
provid exclus use mari ellen eagan leerink pm
reason report
event cover revlimid ip luspatercept result cellular
bottom line american societi hematolog meet
yesterday celgen host analyst investor event
review numer clinic updat late-stag asset luspatercept
liso-cel well phase trial result revlimid
follicular lymphoma ceo mark all gave prepar comment
revlimid patent controversi essenti give assur
gener develop enter market prior celgen
also reiter prior product level guidanc late-stag asset
confirm regulatori file track fedratinib
ozanimod
averag method dcf price
earn price sale
net debt total capit
price-to-earnings lt ep growth
per share per share end
year price history/av daili volume mil celg
creat bluematrix
compani inform leerink partner llc research
revenu million ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
